The AMPK agonist AICAR inhibits the growth of EGFRvIII-expressing glioblastomas by inhibiting lipogenesis

The EGFR/PI3K/Akt/mTOR signaling pathway is activated in many cancers including glioblastoma, yet mTOR inhibitors have largely failed to show efficacy in the clinic. Rapamycin promotes feedback activation of Akt in some patients, potentially underlying clinical resistance and raising the need for al...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Guo, Deliang, Hildebrandt, Isabel J., Prins, Robert M., Soto, Horacio, Mazzotta, Mary M., Dang, Julie, Czernin, Johannes, Shyy, John Y.-J., Watson, Andrew D., Phelps, Michael, Radu, Caius G., Cloughesy, Timothy F., Mischel, Paul S.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: National Academy of Sciences 2009
Konular:
Biological Sciences
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC2714280/
https://ncbi.nlm.nih.gov/pubmed/19625624
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.0906606106
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller